Brief: Aravive Presents Updated Clinical Data At Asco Showing Continued Best-In-Class Potential Of Batiraxcept In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma (Ccrcc)
27/05/2022 24:56
May 26 (Reuters) - Aravive Inc ARAV.O :
* ARAVIVE PRESENTS UPDATED CLINICAL DATA AT ASCO SHOWING
CONTINUED
BEST-IN-CLASS POTENTIAL OF BATIRAXCEPT IN ADVANCED OR METASTATIC
CLEAR CELL RENAL CELL CARCINOMA (CCRCC)
Source text for Eikon: ID:nGNXbQ5NKt
Further company coverage: ARAV.O
((Reuters.Briefs@thomsonreuters.com;))